Lyra Therapeutics appoints Harlan Waksal as Executive Chair; adopts inducement award plan

Lyra Therapeutics, Inc.

Harlan Waksal appointed as Class II director, Chairperson, and Executive Chair; base salary $200,000.
Waksal receives option to purchase 520,000 shares at $4.21, vesting based on market cap targets over 5 years.
CEO Maria Palasis granted option for 175,000 shares; both executives eligible for 1% of market cap bonus on change in control ≥ $750M.
Lyra adopts 2022 Inducement Award Plan reserving 520,000 shares for new hires under Nasdaq Rule 5635(c)(4).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Harlan Waksal

Executive Chair

LYRA · Lyra Therapeutics, Inc.

Effective: 2022-02-16
Filed: February 18, 2022, 6:59 PM ET

On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Harlan Waksal was appointed as Executive Chair at Lyra Therapeutics, Inc..

Action: appointed
Role: Executive Chair

Exact text from the filing

On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.

View on SEC.gov

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-046719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.